Revvity (PKN) Stock Overview

Provides health sciences solutions, technologies, and services. More details

PKN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 30.4% below our estimate of its fair value

Earnings are forecast to grow 19.14% per year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

PKN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Revvity, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Revvity
Historical stock prices
Current Share Price	US$86.94
52 Week High	US$86.94
52 Week Low	US$83.30
Beta	1.11
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	530.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PKN	DE Life Sciences	DE Market
7D	n/a	-3.0%	-2.6%
1Y	n/a	-6.7%	-1.4%

Return vs Industry: Insufficient data to determine how PKN performed against the German Life Sciences industry.

Return vs Market: Insufficient data to determine how PKN performed against the German Market.

Price Volatility

Is PKN's price volatile compared to industry and market?
PKN volatility
PKN Average Weekly Movement	n/a
Life Sciences Industry Average Movement	8.1%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: PKN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine PKN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1937	11,000	Prahlad Singh	www.revvity.com

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.

Revvity, Inc. Fundamentals Summary

How do Revvity's earnings and revenue compare to its market cap?
PKN fundamental statistics
Market cap	€9.76b
Earnings (TTM)	€206.49m
Revenue (TTM)	€2.51b

47.4x

P/E Ratio

3.9x

P/S Ratio

Is PKN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PKN income statement (TTM)
Revenue	US$2.90b
Cost of Revenue	US$1.33b
Gross Profit	US$1.58b
Other Expenses	US$1.34b
Earnings	US$239.11m

Last Reported Earnings

Apr 05, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	2.14
Gross Margin	54.32%
Net Profit Margin	8.24%
Debt/Equity Ratio	44.7%

How did PKN perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

13%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 02:41
End of Day Share Price	2026/06/11 00:00
Earnings	2026/04/05
Annual Earnings	2025/12/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revvity, Inc. is covered by 34 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Catherine Ramsey Schulte	Baird
Charles Butler	Barclays
Luke Sergott	Barclays